Pharmaceutical
Biotechnology
Biopharmaceutical

Alexion Pharmaceuticals

3,423

$112.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+0.13%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!

About ALXN

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

CEO
Ludwig N. Hantson
Employees
3,082
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
24.82B
Price-Earnings Ratio
10.47
Dividend Yield
—
Average Volume
2.40M
High Today
$113.07
Low Today
$110.96
Open Price
$112.06
Volume
1.43M
52 Week High
$134.84
52 Week Low
$72.67

Collections

Pharmaceutical
Biotechnology
Biopharmaceutical
Health
Therapy
Technology
US
North America

ALXN News

ReutersJun 29

BRIEF-Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission

June 29 (Reuters) - Alexion Pharmaceuticals Inc: * ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN
0

ALXN Earnings

$0.00
$1.07
$2.15
$3.22
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Expected Jul 29, Pre-Market

You May Also Like

PGX
CNC
HCCHR
WNGRF
AMKR
FAN
MCI
CFFI
CSTE
TAOP
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy ALXN

Market Price$112.39
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell ALXN stock and options commission-free.
LearnBlogCareersHelpLog InSign Up